1. A Review of Economic Evaluations of Darunavir Boosted by Low-Dose Ritonavir in Treatment-Experienced Persons Living with HIV Infection

   • Josephine Mauskopf
   • Lieven Annemans
   • Erik Smets

   Review Article 14 October 2012 Pages: 1 - 16

   

2. Clinical Management of Treatment-Experienced, HIV/AIDS Patients in the Combination Antiretroviral Therapy Era

   • Mark A. Boyd
   • Andrew M. Hill

   Review Article 14 October 2012 Pages: 17 - 34

   

3. The Impact of Disease Stage on Direct Medical Costs of HIV Management

   • Adrian Levy
   • Karissa Johnston
   • Julio Montaner

   Review Article 14 October 2012 Pages: 35 - 47

   

4. Medical Resource Utilization and Cost of HIV-Related Care in the Highly Active Antiretroviral Therapy Era at a University Clinic in Sweden

   • Ola Ghatnekar
   • Catharina Hjortsberg
   • Mickael Löthgren

   Original Research Article 14 October 2012 Pages: 49 - 57

   

5. The Cost of Managing HIV Infection in Highly Treatment-Experienced, HIV-Infected Adults in France

   • Xavier Colin
   • Antoine Lafuma
   • Pascal Guillon

   Original Research Article 14 October 2012 Pages: 59 - 68

   

6. Costs to Achieve Undetectable HIV RNA with Darunavir-Containing Highly Active Antiretroviral Therapy in Highly Pretreated Patients

   • Andrew M. Hill
   • Bonaventura Clotet
   • Erik Smets

   Original Research Article 14 October 2012 Pages: 69 - 81

   

7. Cost Effectiveness of Darunavir/Ritonavir in Highly Treatment-Experienced, HIV-1-Infected Adults in the USA

   • Josephine Mauskopf
   • Anita Brogan
   • Erik Smets

   Original Research Article 14 October 2012 Pages: 83 - 105

   

8. Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Protease Inhibitor-Experienced, HIV-1-Infected Adults in Belgium, Italy, Sweden and the UK

   • Karen Moeremans
   • Lieven Annemans
   • Erik Smets

   Original Research Article 14 October 2012 Pages: 107 - 128

   

9. US Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, HIV-Infected Adults with Evidence of Protease Inhibitor Resistance Included in the TITAN Trial

   • Anita Brogan
   • Josephine Mauskopf
   • Erik Smets

   Original Research Article 14 October 2012 Pages: 129 - 146

   

10. Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Treatment-Experienced, Lopinavir-Naive, Protease Inhibitor-Resistant, HIV-Infected Adults in Belgium, Italy, Sweden and the UK

    • Karen Moeremans
    • Lindsay Hemmett
    • Erik Smets

    Original Research Article 14 October 2012 Pages: 147 - 167

    

11. Predicting Direct Costs of HIV Care During the First Year of Darunavir-Based Highly Active Antiretroviral Therapy Using CD4 Cell Counts

    • Andrew M. Hill
    • Kelly Gebo
    • Erik Smets

    Original Research Article 14 October 2012 Pages: 169 - 181

    

12. Modelling the Budget Impact of Darunavir in the Treatment of Highly Treatment-Experienced, HIV-Infected Adults in France

    • Xavier Colin
    • Antoine Lafuma
    • Pascal Guillon

    Original Research Article 14 October 2012 Pages: 183 - 197